Literature DB >> 15136064

Inflammation, infection, and aortic valve sclerosis; Insights from the Olmsted County (Minnesota) population.

Yoram Agmon1, Bijoy K Khandheria, A Jamil Tajik, James B Seward, JoRean D Sicks, Angela J Fought, W Michael O'Fallon, Thomas F Smith, David O Wiebers, Irene Meissner.   

Abstract

Atherosclerosis-related mechanisms, including inflammation and possibly infection, are likely to be involved in the pathogenesis of calcific aortic valve disease. The purpose of this study was to examine whether systemic inflammatory markers and Chlamydia pneumoniae seropositivity are associated with aortic valve sclerosis (AVS) in a sample of the general population. Transesophageal echocardiography was performed in 381 subjects (median age: 67 years, range: 51-101; 52% men), a sample of the adult population in Olmsted County, Minnesota. The associations between systemic inflammatory markers (blood counts, including white blood cells differential counts, fibrinogen, and high-sensitivity C-reactive protein [hs-CRP]), C. pneumoniae immunoglobulin G (IgG) antibody titers, and AVS were examined. AVS was present in 140 subjects (37% of the population). After adjustment for age, sex, and smoking status: (1). hs-CRP was associated with AVS (odds ratio: 1.20 per two-fold increase in hs-CRP; 95% confidence interval: 1.01-1.43; P = 0.04) but this association was not significant after adjustment for additional risk factors for AVS, including body mass index (P = 0.52). (2). Blood counts and fibrinogen were not associated with AVS (P-values >0.30). (3). C. pneumoniae IgG antibody titers (low [1:16-1:32], intermediate [1:64-1:128], or high [>or=1:256] titers, compared with titers <1:16) were not associated with AVS (P = 0.21). In conclusion, hs-CRP is weakly associated with AVS, an association that is not independent of other AVS risk factors. Blood counts, fibrinogen, and C. pneumoniae seropositivity are not associated with AVS. These findings suggest that other non-inflammatory non-infectious mechanisms are likely to have a role in the pathogenesis of calcific aortic valve disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15136064     DOI: 10.1016/j.atherosclerosis.2004.01.028

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  15 in total

1.  Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.

Authors:  Luis M Moura; Sandra F Ramos; José L Zamorano; Isabel M Barros; Luis F Azevedo; Francisco Rocha-Gonçalves; Nalini M Rajamannan
Journal:  J Am Coll Cardiol       Date:  2007-01-22       Impact factor: 24.094

2.  Relation between progression of aortic valve sclerosis and carotid intima-media thickening in asymptomatic subjects with cardiovascular risk factors.

Authors:  Yasuko Yamaura; Nozomi Watanabe; Kikuko Obase; Akihiro Hayashida; Hiroyuki Okura; Kiyoshi Yoshida
Journal:  J Echocardiogr       Date:  2010-03-11

3.  Arterial Stiffness in Aortic Stenosis: Relationship with Severity and Echocardiographic Procedures Response.

Authors:  Giuseppe Bruschi; Alessandro Maloberti; Paola Sormani; Giulia Colombo; Stefano Nava; Paola Vallerio; Francesca Casadei; Jolie Bruno; Antonella Moreo; Bruno Merlanti; Claudio Russo; Fabrizio Oliva; Silvio Klugmann; Cristina Giannattasio
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-01-11

Review 4.  Aortic sclerosis: not an innocent murmur but a marker of increased cardiovascular risk.

Authors:  A K Nightingale; J D Horowitz
Journal:  Heart       Date:  2005-03-29       Impact factor: 5.994

5.  Acute myocardial infarction in patients with versus without aortic valve sclerosis and effect of statin therapy (from the Heart and Soul Study).

Authors:  Sanjiv J Shah; Bryan Ristow; Sadia Ali; Bee Ya Na; Nelson B Schiller; Mary A Whooley
Journal:  Am J Cardiol       Date:  2007-02-23       Impact factor: 2.778

Review 6.  Insights into the use of biomarkers in calcific aortic valve disease.

Authors:  Erik Beckmann; Juan B Grau; Rachana Sainger; Paolo Poggio; Giovanni Ferrari
Journal:  J Heart Valve Dis       Date:  2010-07

7.  Association of aortic valve calcification to the presence, extent, and composition of coronary artery plaque burden: from the Rule Out Myocardial Infarction using Computer Assisted Tomography (ROMICAT) trial.

Authors:  Amir A Mahabadi; Fabian Bamberg; Michael Toepker; Christopher L Schlett; Ian S Rogers; John T Nagurney; Thomas J Brady; Udo Hoffmann; Quynh A Truong
Journal:  Am Heart J       Date:  2009-10       Impact factor: 4.749

8.  Left-sided cardiac valvulitis in tristetraprolin-deficient mice: the role of tumor necrosis factor alpha.

Authors:  Sanjukta Ghosh; Mark J Hoenerhoff; Natasha Clayton; Page Myers; Deborah J Stumpo; Robert R Maronpot; Perry J Blackshear
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

Review 9.  Medical therapy for rheumatic heart disease: is it time to be proactive rather than reactive?

Authors:  Nalini M Rajamannan; Francesco Antonini-Canterin; Luis Moura; Jose L Zamorano; Raphael A Rosenhek; Patricia Jm Best; Margaret A Lloyd; F Rocha-Goncalves; Sarat Chandra; Ottavio Alfieri; Patrizio Lancellotti; Pilar Tornos; Ragavendra R Baliga; Andrew Wang; Thomas Bashore; S Ramakrishnan; Konstantinos Spargias; Mony Shuvy; Ronen Beeri; Chaim Lotan; Jassim Al Suwaidi; Vinay Bahl; Luc A Pierard; Gerald Maurer; Gian Luigi Nicolosi; Shahbudin H Rahimtoola; K Chopra; Natesa G Pandian
Journal:  Indian Heart J       Date:  2009 Jan-Feb

10.  Impact of chronic kidney disease on the presence and severity of aortic stenosis in patients at high risk for coronary artery disease.

Authors:  Chiaki Masuda; Kaoru Dohi; Yuko Sakurai; Yuri Bessho; Harumi Fukuda; Shinobu Fujii; Tadafumi Sugimoto; Masaki Tanabe; Katsuya Onishi; Katsuya Shiraki; Masaaki Ito; Tsutomu Nobori
Journal:  Cardiovasc Ultrasound       Date:  2011-11-16       Impact factor: 2.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.